Skip to navigation Skip to content Skip to subnav
Searching 2019-2020 Session

2019-2020 Session

Change Session
Select a session

2007-2008 and Earlier Sessions

S.252

An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration

Sen. Virginia Lyons
Senate Committee on Health and Welfare
1/9/2020 - Read 1st time & referred to Committee on Health and Welfare
Sponsor(s)
Location
Senate Committee on Health and Welfare
Last Recorded Action
Senate 1/9/2020 - Read 1st time & referred to Committee on Health and Welfare
Bill/Resolution Text

NOTE: to print information that appears on a tab within the bill page, use the Print link on that tab.

An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration

Detailed Status

Regular Session 2019-2020
Body Date Journal Calendar Location Full Status
An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration

Roll Call History

Regular Session 2019-2020
Body Date Journal Location Full Status

Back to top

Although procedurally bills and resolutions are assigned to only one committee at a time, other committees may review the bill or resolution. This page contains results from both the assigned committee as well as other committees.

An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration

Committee Meetings

Regular Session 2019-2020
Meeting Date Committee
An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration

Meeting Full List

Regular Session 2019-2020
Friday, January 17, 2020
Committee(s):
Senate Committee on Health and Welfare
-

S.252 - An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration

Walk-through

Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Council

Tuesday, February 4, 2020
Committee(s):
Senate Committee on Health and Welfare
10:45 AM

S.252 - An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration

Walk-through

Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Council

Friday, February 14, 2020
Committee(s):
Senate Committee on Health and Welfare
9:00 AM

S.252 - An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration

Daniel Weiss, Professor of Medicine, Professor of Cell and Molecular Biology, University of Vermont
Cindy Bruzzese, Director, Vermont Ethics Network
Jessa Barnard, Executive Director, Vermont Medical Society
Lauren Hibbert, Director, Office of Professional Regulation, Office of the Secretary of State
Charity Clark, Chief of Staff, Attorney General's Office
Shayla Livingston, Public Health Policy Advisor, Department of Health
Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Council

Tuesday, February 18, 2020
Committee(s):
Senate Committee on Health and Welfare
10:30 AM

S.252 - An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration

Mark-up

Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Council
Cindy Bruzzese, Director, Vermont Ethics Network
Lauren Hibbert, Director, Office of Professional Regulation, Office of the Secretary of State
David Herlihy, Director of Hospital Licensing, Department of Health, Executive Director, Vermont Board of Medical Practice

Tuesday, February 25, 2020
Committee(s):
Senate Committee on Health and Welfare
10:30 AM

S.252 - An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration

Discussion

Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Council

An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration

Witnesses Who Testified

Regular Session 2019-2020
Senate Committee on Health and Welfare
  • Jessa Barnard, Executive Director, Vermont Medical Society
  • Cindy Bruzzese, Director, Vermont Ethics Network
  • Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Council
  • Charity Clark, Chief of Staff, Attorney General's Office
  • David Herlihy, Director of Hospital Licensing, Department of Health, Executive Director, Vermont Board of Medical Practice
  • Lauren Hibbert, Director, Office of Professional Regulation, Office of the Secretary of State
  • Shayla Livingston, Public Health Policy Advisor, Department of Health
  • Daniel Weiss, Professor of Medicine, Professor of Cell and Molecular Biology, University of Vermont

Back to top

Fiscal notes and materials available on this web page are provided for informational purposes only, and may not comprise all materials received by the Vermont Legislature or the final fiscal information related to a specific bill.  The Legislature is not responsible for the accuracy of any information in these materials, and their posting does not constitute approval or endorsement by the Legislature.

No fiscal documents found for S.252 in the Regular Session 2019-2020.
No committee of conference members found for S.252 in the Regular Session 2019-2020.
An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration

Committee of Conference Meetings

Regular Session 2019-2020
Meeting Date Committee
An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration

Committee of Conference Meeting Full List

Regular Session 2019-2020
No committee of conference meeting history found for S.252 in the Regular Session 2019-2020.
No committee of conference report found for S.252 in the Regular Session 2019-2020.

Back to top

Act

No act information found for S.252 in the Regular Session 2019-2020.

Staff & Other Information

Staff
Jennifer Carbee, Deputy Chief Counsel

Back to top